EICHOR
● Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Condition: PROC · Platinum Resistant Ovarian Cancer · Endometrial Cancer · Sponsor: Whitehawk Therapeutics, Inc.
About this study
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.
This description comes directly from the study's public registry record.
Talk to the study team
Clinical Trial Manager Lead · 888-392-9025 · WHWK-Clinical-Trials@whitehawktx.com
Central email mailbox - Whitehawk Therapeutics · WHWK-Clinical-Trials@whitehawktx.com
Always discuss trial participation with your own doctor first.
Locations (12)
| University of Arkansas - Winthrop P. Rockefeller Cancer Institute | Little Rock, Arkansas, United States | Not Yet Recruiting |
| START - Los Angeles | Los Angeles, California, United States | Recruiting |
| SCRI - Florida Cancer Specialists | Sarasota, Florida, United States | Not Yet Recruiting |
| St. Francis Medical Center (OSF Healthcare) | Peoria, Illinois, United States | Not Yet Recruiting |
| Karmanos Cancer Center | Detroit, Michigan, United States | Not Yet Recruiting |
| Start - Ny | Lake Success, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Not Yet Recruiting |
| Atrium Health - Wake Forest | Charlotte, North Carolina, United States | Not Yet Recruiting |
| Ohio State University Wexner Medical Center | Columbus, Ohio, United States | Not Yet Recruiting |
| SCRI - Sydney Kimmel Cancer Center - Jefferson Health | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
| SCRI - Mary Crowley Cancer Research | Dallas, Texas, United States | Not Yet Recruiting |
| START Mountain | Salt Lake City, Utah, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07470853